Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

The Roles of Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 in Cancer and Cancer Stem Cells.

Cao J, Mu Q, Huang H.

Stem Cells Int. 2018 Mar 15;2018:4217259. doi: 10.1155/2018/4217259. eCollection 2018. Review.

2.

Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer.

Lai Y, Sun C.

Oncol Lett. 2018 Feb;15(2):2173-2178. doi: 10.3892/ol.2017.7590. Epub 2017 Dec 12.

3.

Immunohistochemical Study of ER, PR, Ki67 and p53 in Endometrial Hyperplasias and Endometrial Carcinomas.

Masjeed NMA, Khandeparkar SGS, Joshi AR, Kulkarni MM, Pandya N.

J Clin Diagn Res. 2017 Aug;11(8):EC31-EC34. doi: 10.7860/JCDR/2017/28750.10475. Epub 2017 Aug 1.

4.

The genetic landscape of endometrial clear cell carcinomas.

DeLair DF, Burke KA, Selenica P, Lim RS, Scott SN, Middha S, Mohanty AS, Cheng DT, Berger MF, Soslow RA, Weigelt B.

J Pathol. 2017 Oct;243(2):230-241. doi: 10.1002/path.4947. Epub 2017 Sep 5.

PMID:
28718916
5.

Ciliated HPV-related Carcinoma: A Well-differentiated Form of Head and Neck Carcinoma That Can Be Mistaken for a Benign Cyst.

Bishop JA, Westra WH.

Am J Surg Pathol. 2015 Nov;39(11):1591-5. doi: 10.1097/PAS.0000000000000521.

6.

Age at menarche and endometrial cancer risk: a dose-response meta-analysis of prospective studies.

Gong TT, Wang YL, Ma XX.

Sci Rep. 2015 Sep 11;5:14051. doi: 10.1038/srep14051.

7.

Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.

Felix AS, Scott McMeekin D, Mutch D, Walker JL, Creasman WT, Cohn DE, Ali S, Moore RG, Downs LS, Ioffe OB, Park KJ, Sherman ME, Brinton LA.

Gynecol Oncol. 2015 Oct;139(1):70-6. doi: 10.1016/j.ygyno.2015.08.022. Epub 2015 Sep 1.

8.

PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study.

Visser NC, Bulten J, van der Wurff AA, Boss EA, Bronkhorst CM, Feijen HW, Haartsen JE, van Herk HA, de Kievit IM, Klinkhamer PJ, Pijlman BM, Snijders MP, Vandenput I, Vos MC, de Wit PE, van de Poll-Franse LV, Massuger LF, Pijnenborg JM.

BMC Cancer. 2015 Jun 30;15:487. doi: 10.1186/s12885-015-1487-3.

9.

Current status of molecular-targeted drugs for endometrial cancer (Review).

Nogami Y, Banno K, Kisu I, Yanokura M, Umene K, Masuda K, Kobayashi Y, Yamagami W, Nomura H, Tominaga E, Susumu N, Aoki D.

Mol Clin Oncol. 2013 Sep;1(5):799-804. Epub 2013 Jun 26.

10.

The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.

Fadare O, Gwin K, Desouki MM, Crispens MA, Jones HW 3rd, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL, Parkash V.

Mod Pathol. 2013 Aug;26(8):1101-10. doi: 10.1038/modpathol.2013.35. Epub 2013 Mar 22.

11.

Clear cell carcinomas of the mullerian system: does the pathogenesis vary depending on their nuclear grade and their association with endometriosis? An immunohistochemical analysis.

Alduaij A, Hansen K, Karim TA, Zhang C, Lomme MM, Sung CJ, Lawrence WD, Quddus MR.

Patholog Res Int. 2012;2012:674748. doi: 10.1155/2012/674748. Epub 2012 Nov 1.

12.

Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study.

Yang HP, Wentzensen N, Trabert B, Gierach GL, Felix AS, Gunter MJ, Hollenbeck A, Park Y, Sherman ME, Brinton LA.

Am J Epidemiol. 2013 Jan 15;177(2):142-51. doi: 10.1093/aje/kws200. Epub 2012 Nov 21.

13.

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

Birkeland E, Wik E, Mjøs S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Øyan AM, Kalland KH, Akslen LA, Simon R, Krakstad C, Salvesen HB.

Br J Cancer. 2012 Dec 4;107(12):1997-2004. doi: 10.1038/bjc.2012.477. Epub 2012 Oct 25.

14.

p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans.

Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner M, Georgiev S, Fankhauser N, Noske A, Roessle M, Caduff R, Dellas A, Fink D, Moch H, Krek W, Frew IJ.

EMBO Mol Med. 2012 Aug;4(8):808-24. doi: 10.1002/emmm.201101063. Epub 2012 Jun 8.

15.

Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.

Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, Konner J.

Int J Gynecol Cancer. 2012 Jun;22(5):807-11. doi: 10.1097/IGC.0b013e31824a33a2.

16.

Molecular pathogenesis of endometrial and ovarian cancer.

Merritt MA, Cramer DW.

Cancer Biomark. 2010;9(1-6):287-305. doi: 10.3233/CBM-2011-0167. Review.

17.

Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome.

Masuda K, Banno K, Yanokura M, Kobayashi Y, Kisu I, Ueki A, Ono A, Nomura H, Hirasawa A, Susumu N, Aoki D.

Curr Genomics. 2011 Mar;12(1):25-9. doi: 10.2174/138920211794520169.

18.

Genetics of endometrial cancers.

Okuda T, Sekizawa A, Purwosunu Y, Nagatsuka M, Morioka M, Hayashi M, Okai T.

Obstet Gynecol Int. 2010;2010:984013. doi: 10.1155/2010/984013. Epub 2010 Apr 8.

19.

Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, Dimopoulos MA, Papadimitriou CA.

Obstet Gynecol Int. 2010;2010:749579. doi: 10.1155/2010/749579. Epub 2010 Feb 2.

20.

Insights into endometrial serous carcinogenesis and progression.

Fadare O, Zheng W.

Int J Clin Exp Pathol. 2009;2(5):411-32. Epub 2009 Jan 10.

Supplemental Content

Support Center